Docetaxel for advanced prostate cancer: how early to start?
Mené en France sur 413 patients atteints d'un cancer localisé de la prostate à haut risque (durée médiane de suivi : 8,8 ans), cet essai multicentrique évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité de l'ajout d'une chimiothérapie combinant docétaxel et estramustine à un anti-androgène (goséréline)
Docetaxel emerged as a survival-prolonging drug in men with metastatic castration-resistant prostate cancer more than 10 years ago, on the basis of two parallel studies showing a 20–30% relative improvement in overall survival compared with mitoxantrone chemotherapy, with a median improvement of 2–3 months. In 2014, the efficacy of docetaxel in men with metastatic castration-sensitive prostate cancer was shown by the investigators of the ECOG CHAARTED trial, who reported an almost 40% relative improvement in overall survival, increasing overall survival by 13 months (by 17 months in men with high volume disease) compared with androgen-deprivation therapy alone.
The Lancet Oncology , commentaire, 2014